Closing the Gaps in NSCLC

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
Sponsored by

Episodes 1-16 of 20

- Jennifer Caudle, DO
  Peer
- Stephen Liu, MD
  Peer
2
Closing the Gaps in NSCLC
Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer
Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer
Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Ca...
- Stephen Liu, MD
  Peer
1
Closing the Gaps in NSCLC
How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
- Edward S. Kim, MD
  Peer
0
Closing the Gaps in NSCLC
Understanding the Importance of RET Mutation as a Primary Oncogenic Driver
Understanding the Importance of RET Mutation as a Primary Oncogenic Driver
Understanding the Importance of RET Mutation as a Primary Oncogenic Driver
- Michael R. Shafique, MD
  Peer
0
Closing the Gaps in NSCLC
Keys to Successful Maintenance Therapy for Advanced NSCLC
Keys to Successful Maintenance Therapy for Advanced NSCLC
Keys to Successful Maintenance Therapy for Advanced NSCLC
- Paul P. Doghramji, MD, FAAFP
  Peer
- Edward S. Kim, MD
  Peer
1
Closing the Gaps in NSCLC
Creating Targeted Treatment Pathways Driven by Genomic Makeup & Cancer Type
Creating Targeted Treatment Pathways Driven by Genomic Makeup & Cancer Type
Creating Targeted Treatment Pathways Driven by Genomic Makeup & Cancer Type
- Michael R. Shafique, MD
  Peer
0
Closing the Gaps in NSCLC
An Oncologist’s Priorities for Managing Adverse Events in NSCLC Care
An Oncologist’s Priorities for Managing Adverse Events in NSCLC Care
An Oncologist’s Priorities for Managing Adverse Events in NSCLC Care
- Paul Doghramji, MD
  Peer
- Tony Y. Hu, PhD
  Peer
0
Closing the Gaps in NSCLC
Current & Future Innovations in Lung Cancer Detection
Current & Future Innovations in Lung Cancer Detection
Current & Future Innovations in Lung Cancer Detection
- Paul Doghramji, MD
  Peer
- Tony Y. Hu, PhD
  Peer
0
Closing the Gaps in NSCLC
Investigating a Potential Serum Biomarker for Lung Cancer
Investigating a Potential Serum Biomarker for Lung Cancer
Investigating a Potential Serum Biomarker for Lung Cancer
- Amit Bobby Mahajan, MD, FCCP, DAABIP
  Peer
0
Closing the Gaps in NSCLC
NSCLC State of the Union: Where We Are & Where We're Going
NSCLC State of the Union: Where We Are & Where We're Going
NSCLC State of the Union: Where We Are & Where We're Going
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
On the Forefront of NSCLC Treatment: Targeting RET Mutations
On the Forefront of NSCLC Treatment: Targeting RET Mutations
On the Forefront of NSCLC Treatment: Targeting RET Mutations
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
Fulfilling the Unmet Needs of NSCLC Patients
Fulfilling the Unmet Needs of NSCLC Patients
Fulfilling the Unmet Needs of NSCLC Patients
- Jennifer Caudle, DO
  Peer
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
New Approaches to Treating Non-Small Cell Lung Cancer
New Approaches to Treating Non-Small Cell Lung Cancer
New Approaches to Treating Non-Small Cell Lung Cancer
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
The Importance of Symptom Management for NSCLC Patients
The Importance of Symptom Management for NSCLC Patients
The Importance of Symptom Management for NSCLC Patients
- Fred R. Hirsch, MD, PhD
  Peer
0
Closing the Gaps in NSCLC
The Role of Oncogene Addiction in RET Mutations & Treatment Selection
The Role of Oncogene Addiction in RET Mutations & Treatment Selection
The Role of Oncogene Addiction in RET Mutations & Treatment Selection
- Jacob Sands, MD
  Peer
2
Closing the Gaps in NSCLC
Next Generation Sequencing in Lung Squamous Cell Carcinoma
Next Generation Sequencing in Lung Squamous Cell Carcinoma
Next Generation Sequencing in Lung Squamous Cell Carcinoma
- Jacob Sands, MD
  Peer
0
Closing the Gaps in NSCLC
Components to a Comprehensive Lung Cancer Screening Program
Components to a Comprehensive Lung Cancer Screening Program
Components to a Comprehensive Lung Cancer Screening Program